XOMA xoma.com: Rasio Kapitalisasi Pasar marang Nilai Buku

XOMA Royalty (XOMA) demonstrates high resilience to global conflicts due to the humanitarian status of biomedicine. This stability is paired with an efficient asset-light model, where the absence of testing costs ensures flawless margins and predictable FCF. The linear price action on this chart corresponds to the 5.14 indicator. Business growth is based on the ownership of rights to more than 70 assets and the success of partner drugs, such as Vabysmo.

For a portfolio manager, this indicator serves as a tool to assess the market premium over net asset value, determining the value of each dollar of equity. By analyzing the market's revaluation coefficient of balance sheet capital, the investor can see the extent to which the value of XOMA Royalty (XOMA) royalty rights exceeds the value of its assets, which is critical for a model based on income from third-party developments without internal R&D costs.